MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.farma.2024.04.006

Медицинская библиотека · Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 2024

Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study.

Chamorro-de-Vega Esther, Calvo Alberto, Fernández-Pacheco María, Hernández-Muniesa Belén, Romero-Jiménez Rosa, Casado-Gómez Araceli, Ramírez Esther, Grupo de Trabajo Estudio SACVINFA:, Morell Alberto, Herrero Nuria, Úbeda Bárbara, Ais-Larisgoitia Arantza, Lobato-Matilla Elena, Muñoz Álvaro, Casado Miguel Ángel, Escudero-Vilaplana Vicente

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

To evaluate health-related quality of life perceived by patients with the most prevalent immune-mediated inflammatory diseases in Spain: inflammatory bowel disease (IBD), psoriasis (Ps), psoriatic arthritis (AP), rheumatoid arthritis (RA), and spondyloarthropathies (SpAs), and to determine the factors that influence patient quality of life.

METHODS

The SACVINFA study (SA=satisfaction, CV=quality of life, IN=immune-mediated, FA=pharmacy) consisted of an observational study conducted in 4 hospitals in the Community of Madrid. A cross-sectional analysis was made for adult patients diagnosed with an immune-mediated inflammatory disease who attended the Pharmacy Service. Quality of life was assessed using the EQ-5D-5L questionnaire (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and specific questionnaires: SIBDQ-9, DLQI, PsAQoL, QoL-RA, and ASQoL.

RESULTS

A total of 578 patients were analysed (inflammatory bowel disease=25.3%; psoriasis=19.7%; spondyloarthropathies=18.7%; rheumatoid arthritis=18.5%; psoriatic arthritis=17.8%). The mean age (standard deviation) was 49.8 (12.3) years and 50.7% were male. The average score (standard deviation) for the global EQ-5D-5L was 0.771 (0.2) and the mean (standard deviation) visual analogue scale score was 71.5 (20.0). Type of immune-mediated inflammatory diseases was associated with differences in quality of life showing psoriasis and inflammatory bowel disease higher values of EQ5D-5L than psoriatic arthritis, rheumatoid arthritis, and spondyloarthropathies, p<.05 in all comparisons. Patients with RA, IBD, and Ps achieved 70% of the maximum score, while patients with PsA and SpAs did not reach 50% of the maximum possible score. Female gender, a state of moderate/severe disease severity, an older age, and a higher number of previous treatments were correlated with worse quality of life. Conversely, persistence to current treatment correlated with better quality of life.

CONCLUSIONS

Patients with immune-mediated inflammatory diseases have markedly affected quality of life, mainly in the pain/discomfort dimension, especially in those immune-mediated inflammatory diseases with a rheumatological component.

Для цитирования: Chamorro-de-Vega Esther, Calvo Alberto, Fernández-Pacheco María, Hernández-Muniesa Belén, Romero-Jiménez Rosa, Casado-Gómez Araceli, Ramírez Esther, Grupo de Trabajo Estudio SACVINFA:, Morell Alberto, Herrero Nuria, Úbeda Bárbara, Ais-Larisgoitia Arantza, Lobato-Matilla Elena, Muñoz Álvaro, Casado Miguel Ángel, Escudero-Vilaplana Vicente. Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study.. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2024. DOI: 10.1016/j.farma.2024.04.006.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.